Why use a pre-filled research pen
You cant eat (nausea, vomiting, diarrhea, inhibition of hunger centers of brain)
This CoolSculpting package allows you to target a defined treatment area, including the lower abdomen, full abdomen, flanks, back, neck and chin, or inner and outer thighs, all for one set package price
The GIP receptor activation is not incidental
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
